The influence of alcohol consumption on outcome in patients with peripheral artery disease (PAD) has not been thoroughly studied. Methods: Factores de Riesgo y ENfermedad Arterial (FRENA) is an ongoing, multicenter, observational registry of consecutive stable outpatients with arterial disease. We compared the mortality rate and the incidence of subsequent ischemic events in patients with PAD, according to their alcohol habits. 
Moderate alcohol consumption by apparently healthy people is associated with lower cardiovascular morbidity and mortality than in abstainers. [1] [2] [3] [4] [5] [6] [7] [8] A number of observational studies in patients with coronary or cerebrovascular disease suggest that light to moderate alcohol consumption may also be associated with a lower mortality, [9] [10] [11] [12] [13] [14] [15] [16] but there is no available information on its influence on outcome in patients with peripheral artery disease (PAD). Consequently, guidelines in this area are based on experts' consensus rather than on clinical evidence. [17] [18] [19] The Factores de Riesgo y ENfermedad Arterial (FRENA) Registry was initiated in March 2003 to prospectively record the current clinical management and outcome of patients with arterial disease in Spain. It is an ongoing, multicenter, observational registry of consecutive patients designed to gather and analyze data on treatment patterns and outcomes in stable outpatients with symptomatic ischemic disease of the heart, brain, and/or major peripheral arteries. Data from this registry have been used to study the influence of body weight, smoking habit, or glucose control on outcome. [20] [21] [22] The aim of the current study was to compare the mortality rate and the incidence of subsequent ischemic events in patients with PAD, according to their alcohol habit.
PATIENTS AND METHODS
Inclusion criteria. Participating hospitals in the FRENA registry prospectively enrolled consecutive outpatients with symptomatic artery disease with at least one recent (Ͻ3 months prior to enrollment) episode of coronary artery disease (manifesting as angina or acute coronary syndrome); cerebrovascular disease (manifesting as transient ischemic attack or ischemic stroke); or PAD (either intermittent claudication with an ankle-brachial index Ͻ0.9, or previous vascular intervention or limb amputation for PAD). Patients were excluded if they would not be available for follow-up, or if they were currently participating in a therapeutic clinical trial with a blinded therapy. All patients provided written or oral consent prior to their participation in the registry, according to the requirements of the ethics committee within each hospital.
Study design. For this study, only patients with PAD were considered. The Fontaine classification was used for PAD categorization. 23 Upon entry into the FRENA registry, patients were asked about the daily amount and type of alcohol beverage. Then, at the 4-month visits, they were asked again for any change in their habits. For the purpose of this study, patients were categorized as alcohol consumers or non-consumers. The primary outcome was overall death during the study period. The secondary outcome was the incidence of subsequent ischemic events (myocardial infarction, ischemic stroke, or disabling claudication/critical limb ischemia).
Definitions. Myocardial infarction was defined as a transient increase of creatine kinase-MB or troponin in combination with ischemic symptoms and/or typical electrocardiogram signs (development of pathologic Q-waves or ST-segment elevation or depression). Ischemic stroke was diagnosed if the patient had an appropriate clinical event not resolving completely within 24 hours, and had a brain computed tomography (CT) or magnetic resonance imaging (MRI) that showed a compatible low-density lesion. Disabling claudication/critical limb ischemia was considered in patients with intermittent claudication when needing angioplasty, stenting, or surgery. In patients with Fontaine stages III or IV, critical limb ischemia was considered when needing amputation. A patient was classified as having diabetes when there was a clinical history of diabetes or when they were taking insulin or oral antidiabetic agents. Patients were classified as having hypertension when there was a clinical history of hypertension or when they were taking antihypertensive medications. Creatinine clearance was calculated according to the Cockcroft and Gault formula.
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Follow up. A detailed history was performed on all patients at study entry (Ͻ3 months after an acute ischemic episode). Comorbid conditions were characterized, including a history of coronary artery disease, cerebrovascular disease or PAD, diabetes mellitus, hypertension, hyperlipidemia, chronic lung disease, chronic heart failure, cancer, smoking status, and alcohol consumption. Then, physical examination was performed comprising weight, height, heart rate, and blood pressure on standard conditions, after 5 minutes of rest. An electrocardiogram was also recorded. After the initial visit, patients were followed up at 4-month intervals for at least 12 months. At these visits, any change in medical history and data from physical examination was recorded, with special attention to risk factors; laboratory tests; lifestyle habits; the type, dose, and duration of treatment received, and clinical outcome. Physicians were allowed to use any and all appropriate medications, as dictated by their usual clinical practice patterns.
Data collection. The attending physicians ensured that eligible patients were consecutively enrolled. Data were recorded on to a computer-based case report form at each participating hospital and submitted to a centralized coordinating center through a secure Web site. Patient identities remain confidential because they were identified by a unique number assigned by the study coordinating center, which was responsible for all data management. Data quality was regularly monitored and documented electronically to detect inconsistencies or errors, which are resolved by the local coordinators. Data quality was also monitored by periodic visits to participating hospitals by contract research organizations that compared the medical records with the data in the web. A data audit was performed at periodic intervals. Statistical analysis. Categorical variables were compared using the 2 test (two-sided) and Fisher exact test (two-sided). Odds ratios and corresponding 95% confidence intervals (CI) were calculated, and a P value of Ͻ.05 was considered to be statistically significant. Incidence rates were calculated as cumulative incidence (events/100 patient-years) and compared using the rate ratio. 25 Also, a life table analysis was used to report follow-up events. The association between consumption of alcohol and outcome was assessed using the Cox proportional hazards regression model, estimated by a forward step method. All variables achieving a significance level of Յ0.1 in univariate analysis were considered for inclusion in the logistic regression model. Statistical analyses were conducted with SPSS for Windows Release 17.0 (SPSS, Inc, Chicago, Ill).
RESULTS
As of August 2010, 1073 patients with PAD were recruited in FRENA (29 refused enrollment), of whom 863 patients (80%) had intermittent claudication (Fontaine stage II), 102 (9.5%) had pain at rest (Fontaine stage III), and 108 (10%) had ischemic skin lesions (Fontaine stage IV). In all, 422 patients (39%) consumed alcohol during the study period (wine 312, beer 167, liquors 65). Of these, 151 (36%) consumed Ͻ20 g daily (ie, one can/bottle of beer, glass of wine), 193 (46%) consumed 21 to 60 g/day (ie, 1000 mL of beer, 500 mL of wine), and 78 consumed Ͼ60 g/day.
Alcohol consumers were 4 years younger, more likely male and current smokers, and had hypertension, diabetes, chronic heart failure, atrial fibrillation, or prior coronary heart disease less often than non-consumers (Table I) . They presented more likely with Fontaine stage II, and less likely with Fontaine stage IV, they had higher mean serum levels of creatinine clearance and cholesterol (total and highdensity lipoprotein cholesterol), and were less likely to receive diuretics, beta-blockers, anticoagulants, or insulin than non-consumers.
Over a mean follow-up of 13 months (range, 3-46 months), 150 patients (17%) developed subsequent ischemic events (myocardial infarction 28, stroke 30, disabling claudication/critical limb ischemia 100), and 70 patients (6.5%) died. The incidence of subsequent ischemic events was similar in alcohol consumers and non-consumers, but the mortality rate was significantly lower in alcohol consumers: 2.78 versus 6.58 deaths per 100 patient-years; rate ratio: 0.42; 95% CI, 0.23 to 0.74 (P ϭ .002). This lower mortality was consistently found in patients with Fontaine stages II and III or IV (Tables II and III) . However, there were no significant differences in mortality according to either the amount of alcohol or the type of beverage: the mortality rate was 2.60 (95% CI, 0.95-5.76) per 100 pa- Patients who died were significantly older, weighed less, and more likely to have comorbid diseases (cancer, chronic heart failure, atrial fibrillation, or renal insufficiency) than those who survived. In addition, they presented more often with Fontaine stage III or IV, and were more likely to have received diuretics or anticoagulants, but less likely to have received statins (Table IV) . On multivariate analysis, alcohol consumption was independently associated with a lower mortality (relative risk: 0.49; 95% CI, 0.27-0.88; P ϭ .016), as depicted in Table V . Alcohol consumers had a significantly lower incidence of cardiovascular deaths (1.2% vs 4.2%; P ϭ .008) and a nonsignificantly lower rate of non-cardiovascular deaths (2.4% vs 4.3%; P ϭ .094), as shown in Table VI .
DISCUSSION
Alcohol consumption by apparently healthy people is associated with lower cardiovascular morbidity and mortality than in abstainers, [1] [2] [3] [4] [5] [6] [7] [8] but its role among patients with established arterial disease is less clear. Some observational studies in patients with a history of coronary heart disease, [9] [10] [11] [12] [13] [14] one study in patients with cerebrovascular disease, 15 and a recent meta-analysis 16 concluded that light to moderate alcohol consumption was associated with a significantly lower mortality. Three cohort studies performed in a series of adults from The Netherlands, 6 Greece, 7 and the United States, 8 found that moderate alcohol consumption was associated with a lower prevalence of PAD. Our data reveal that, in patients with PAD, alcohol consumption is also associated with a significantly lower mortality, and this decreased mortality was mainly due to a decrease in the incidence of cardiovascular deaths. This better outcome was consistently found in patients presenting at different stages of the disease (Fontaine stages II and III or IV), and persisted after multivariate adjustment. Thus, the findings in this study complement existing knowledge regarding the impact of alcohol consumption on outcome in patients with arterial disease.
The 2006 Diet and Lifestyle Recommendations Scientific Statement from the American Heart Association Nutrition Committee advises alcohol consumers to do so in moderation. 17 This means an average of one to two drinks per day for men and one drink per day for women. Drinking more alcohol may increase alcoholism, high blood pressure, obesity, stroke, breast cancer, suicide, or accidents. Furthermore, it is not possible to predict in which people alcoholism will become a problem. Given these and other risks, the American Heart Association cautions people not to start drinking if they do not already drink alcohol. 26 However, some concern has been raised regarding whether it is advisable to encourage people who already drink to maintain a lifestyle that includes moderate alcohol intake rather than abstain completely. 19, 27, 28 Over the past several decades, many studies have been published about how drinking alcohol may be associated with reduced mortality in some populations. Some mechanisms cited for the protective effect of moderate alcohol consumption on outcome include its antiatherogenic role in increasing the levels of high density lipoprotein cholesterol, 29 its hemostatic effects by decreasing platelet aggregation 30 and increasing fibrinolytic activity, 31, 32 and its possible association with beneficial changes in insulin and glucose metabolism. [33] [34] [35] [36] In our study, we failed to find any difference in the mean levels of high-density lipoprotein cholesterol according to alcohol consumption.
Some limitations of our research merit emphasis. First, in our study, alcohol consumers were 4 years younger, had fewer comorbidities, and less likely received diuretics, betablockers, anticoagulants, or insulin than non-consumers. Thus, the better outcome in this study may reflect preexisting, unrecognized diseases, even after making careful exclusions. Hence, despite our efforts to control any bias from underlying diseases, it is likely that we were unable to eliminate such bias completely. Second, people who drink in moderation may have a different lifestyle from people who do not drink, and the apparent healthy effects associated with moderate alcohol consumption may be mostly due to favorable risk profiles in consumers. Third, any information concerning alcohol consumption was based exclusively on the patient's report, with no objective confirmation. Fourth, the lack of information on length of alcohol consumption prior to study entry may also limit our conclusions since patients may modify their drinking habits shortly after the diagnosis of arterial disease, usually reducing their alcohol intake. Finally, alcohol consumption is just one of several predictors of outcome in patients with PAD. Unfortunately, randomized controlled trials to assess the influence of alcohol consumption in patients with arterial disease are not feasible for several reasons, including ethical considerations, so we have to rely on data from observational studies.
The study also has several strengths. To the best of our knowledge, this is the first time the influence of alcohol consumption on outcome has been assessed in a series of patients with PAD. We gathered data on important cardiovascular risk factors (such as smoking status, renal function, and cholesterol levels), continuation of alcohol consumption during follow-up, and medication use. Moreover, we did not exclude patients with underlying diseases or cancer.
The FRENA registry provides insights into the natural history of arterial disease with an unselected patient population, in contrast to the rigorously controlled conditions of randomized clinical studies. It can, therefore, help to identify factors associated with better or worse patient outcomes, and provide feedback from real-world clinical situations, which may be valuable when designing new randomized clinical studies. Our data are hypothesis- generating and provide feedback from real-world clinical situations. In summary, our data reveal that moderate alcohol consumption is associated with a lower mortality in patients with PAD. This better outcome persisted after adjusting for potential confounders, and was apparent at different stages of the disease. Our current findings suggest that alcohol consumers with PAD should continue to drink with moderation. However, translating the results of observational cohort studies into clinical recommendations is premature. 
